CN116459304A - 一种降尿酸组合物及其制备方法 - Google Patents
一种降尿酸组合物及其制备方法 Download PDFInfo
- Publication number
- CN116459304A CN116459304A CN202310502801.7A CN202310502801A CN116459304A CN 116459304 A CN116459304 A CN 116459304A CN 202310502801 A CN202310502801 A CN 202310502801A CN 116459304 A CN116459304 A CN 116459304A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- ethanol
- water
- filtrate
- filtering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 39
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229940116269 uric acid Drugs 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000001603 reducing effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 24
- 238000000605 extraction Methods 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 239000000706 filtrate Substances 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 32
- 238000010298 pulverizing process Methods 0.000 claims description 29
- 239000000341 volatile oil Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 abstract description 2
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000276331 Citrus maxima Species 0.000 abstract 1
- 235000001759 Citrus maxima Nutrition 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 238000002791 soaking Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药技术领域,具体地说,涉及一种降尿酸组合物及其制备方法。所述的降尿酸组合物由如下重量份的原料制成:槐花10~30重量份、荷叶10~20重量份、车前草10~20重量份、化橘红10~20重量份和西红花5~15重量份。本发明制备工艺科学合理,充分考虑了各种中药材的药性和组成,通过优化原材料的提取工艺,保留了药材的绝大部分活性成分,提高了药物的提取率并有效的去除了药材中的杂质,提高了药物的药效及稳定性。
Description
技术领域
本发明属于中药技术领域,具体地说,涉及一种降尿酸组合物及其制备方法。
背景技术
高尿酸血症是机体内嘌呤代谢紊乱引起的尿酸生成增加或***减少的一种常见的代谢性疾病。血尿酸在机体内达到饱和可在关节局、肾脏等部形成尿酸钠结晶,引发局部炎症和组织损伤,诱发痛风、急性肾病、慢性间质性肾炎或肾结石。高尿酸血症累及多***的全身性疾病,是引发疼风、心血管疾病、肾病、高血压等疾病的独立危险因素,是造成过早死亡的独立预测因子。
黄嘌呤氧化酶能够将摄入的黄嘌呤转化成尿酸,是人体内尿酸产生过程的关键酶,通过抑制其活性可以有效降低体内尿酸水平,是目前多种化学药物的作用靶点。比如临床上一线使用的黄嘌呤抑制剂就有别嘌醇、非布司他等药物。通过机体内黄嘌呤氧化酶进行干预,是预防和治疗高尿酸血症的有效措施。
化学药虽然疗效显著,但也存在许多毒副作用,尤其对于我国人群,在使用别嘌醇时容易引发超敏反应,非布司他同样有潜在的心血管风险。因此,寻找安全、有效的降尿酸药一直是医药领域的研究热点。
我国有着丰富中药资源和医药典籍,为寻找治疗降尿酸药物研发提供了方向。越来越多研究表明,中药对降尿酸具有多靶点、毒副作用少、标本兼治的优势,是化学药物所不具备的。
有鉴于此,特提出本发明。
发明内容
本发明的目的在于提供一种降尿酸组合物及其制备方法。
为实现上述目的,本发明采用如下技术方案:
一种降尿酸组合物,其中,所述的降尿酸组合物由如下重量份的原料制成:
优选,所述的降尿酸组合物由如下重量份的原料制成:
本发明还提供所述的降尿酸组合物的制备方法,其包括如下步骤:
(1)将荷叶粉碎、超临界CO2法提取挥发油,挥发油备用;
(2)将槐花和西红花粉碎后蒸馏法提取挥发油,挥发油备用;
(3)蒸馏后的水溶液滤过,得滤液,滤渣用水煎煮,滤过,得水煎液,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用乙醇作为提取液,微波辐照提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理,静置,滤过,滤液回收乙醇并减压浓缩成浸膏;
(6)向浸膏中加入药学上可接受的辅料,搅拌均匀,真空干燥后粉碎,过筛,制粒,干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
进一步地,步骤(1)中,所述的超临界CO2法为:将荷叶粉碎后所得的干粉置于超临界CO2萃取釜中,在温度为45-50℃、压力为25-30MPa、CO2流量为20-25kg/h的条件下萃取1.5-2h,收集挥发油。
进一步地,步骤(4)中,所述的微波辐照提取为:在微波输出功率为500W-800W下辐照10-18分钟进行提取。
进一步地,步骤(4)中,所述的乙醇为65-85%的乙醇,其用量为药材质量的10-15倍。
进一步地,步骤(5)中,超声处理时间为20-30分钟,静置时间为10-20小时。
进一步地,步骤(5)中,所述的减压浓缩为减压浓缩至80℃时相对密度为1.12-1.20的浸膏。
进一步地,所述的步骤(3)为:将蒸馏后的水溶液滤过,药渣用5-10倍药材量的水煎煮1-3次,每次0.5-1.5h,滤过,合并滤液及水煎液成水提取物,药渣备用。
进一步地,所述的药学上可接受的辅料为淀粉、糊精、乳糖、羟甲基纤维素钠或微粉硅胶。
进一步地,所述的步骤(2)为:将槐花和西红花粉碎后先用8-12倍药材量的水进行浸泡4-8小时,再蒸馏提取6-8小时。
与现有技术相比,本发明具有如下优点:
(1)本发明制备工艺科学合理,充分考虑了各种中药材的药性和组成,通过优化原材料的提取工艺,将荷花采用超临界CO2法提取,槐花和西红花采用蒸馏法提取,充分保留了药材的绝大部分活性成分,提高了药物的提取率并有效的去除了药材中的杂质,提高了药物的药效及稳定性;
(2)采用微波辅助提取对药材进行提取,没有高温热源,消除了热梯度,从而使提取质量大大提高,有效保护药材中的有效成分,由于微波可穿透式加热,提取的时间大大节省,微波能有超常的提取能力,在微波场下可一次提净,大大简化工艺流程。微波提取物纯度高,提取温度低,不易糊化,分离容易,后处理方便,节省能源;
(3)与现有的制备工艺相比,本发明所提供的方法制备的降尿酸组合物的纯度和疗效都得到提高,具有非常大的临床意义、社会意义,同时也具有良好的经济效益和应用前景。
具体实施方式
以下为本发明的具体实施方式,所述的实施例是为了进一步描述本发明,而不是限制本发明。
实施例1
称取如下配比的原材料:
其制备方法包括如下步骤:
(1)先将荷叶粉碎,再将粉碎所得的干粉置于超临界CO2萃取釜中,在温度为48℃、压力为28MPa、CO2流量为22kg/h的条件下萃取1.8h,收集挥发油,备用;
(2)将槐花和西红花粉碎后先用10倍药材量的水进行浸泡6小时,再蒸馏提取7小时,收集挥发油,备用;
(3)将蒸馏后的水溶液滤过,药渣用8倍药材量的水煎煮2次,每次1h,滤过,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用药材质量的12倍的75%的乙醇作为提取液,在微波输出功率为600W下辐照15分钟进行提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理25分钟,静置15小时,滤过,滤液回收乙醇并减压浓缩至80℃时相对密度为1.12-1.20的浸膏;
(6)向浸膏中加入适量淀粉,搅拌均匀,真空干燥后粉碎,过筛,加入95%的乙醇制粒,制粒后干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
实施例2
称取如下配比的原材料:
其制备方法包括如下步骤:
(1)先将荷叶粉碎,再将粉碎所得的干粉置于超临界CO2萃取釜中,在温度为45℃、压力为25MPa、CO2流量为20kg/h的条件下萃取1.5h,收集挥发油,备用;
(2)将槐花和西红花粉碎后先用8倍药材量的水进行浸泡4小时,再蒸馏提取6小时,收集挥发油,备用;
(3)将蒸馏后的水溶液滤过,药渣用5倍药材量的水煎煮1次,每次0.5h,滤过,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用药材质量的10倍的65%的乙醇作为提取液,在微波输出功率为500W下辐照10分钟进行提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理20分钟,静置10小时,滤过,滤液回收乙醇并减压浓缩至80℃时相对密度为1.12-1.20的浸膏;
(6)向浸膏中加入适量糊精,搅拌均匀,真空干燥后粉碎,过筛,加入95%的乙醇制粒,制粒后干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
实施例3
称取如下配比的原材料:
其制备方法包括如下步骤:
(1)先将荷叶粉碎,再将粉碎所得的干粉置于超临界CO2萃取釜中,在温度为50℃、压力为30MPa、CO2流量为25kg/h的条件下萃取2h,收集挥发油,备用;
(2)将槐花和西红花粉碎后先用12倍药材量的水进行浸泡8小时,再蒸馏提取8小时,收集挥发油,备用;
(3)将蒸馏后的水溶液滤过,药渣用10倍药材量的水煎煮3次,每次1.5h,滤过,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用药材质量的15倍的85%的乙醇作为提取液,在微波输出功率为800W下辐照18分钟进行提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理30分钟,静置20小时,滤过,滤液回收乙醇并减压浓缩至80℃时相对密度为1.12-1.20的浸膏;
(6)向浸膏中加入适量乳糖,搅拌均匀,真空干燥后粉碎,过筛,加入95%的乙醇制粒,制粒后干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
实施例4
称取如下配比的原材料:
其制备方法包括如下步骤:
(1)先将荷叶粉碎,再将粉碎所得的干粉置于超临界CO2萃取釜中,在温度为46℃、压力为26MPa、CO2流量为23kg/h的条件下萃取1.6h,收集挥发油,备用;
(2)将槐花和西红花粉碎后先用9倍药材量的水进行浸泡4小时,再蒸馏提取7小时,收集挥发油,备用;
(3)将蒸馏后的水溶液滤过,药渣用6倍药材量的水煎煮2次,每次0.8h,滤过,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用药材质量的13倍的70%的乙醇作为提取液,在微波输出功率为650W下辐照12分钟进行提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理22分钟,静置18小时,滤过,滤液回收乙醇并减压浓缩至80℃时相对密度为1.12-1.20的浸膏;
(6)向浸膏中加入适量羟甲基纤维素钠,搅拌均匀,真空干燥后粉碎,过筛,加入95%的乙醇制粒,制粒后干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
实施例5
称取如下配比的原材料:
其制备方法包括如下步骤:
(1)先将荷叶粉碎,再将粉碎所得的干粉置于超临界CO2萃取釜中,在温度为47℃、压力为27MPa、CO2流量为24kg/h的条件下萃取1.8h,收集挥发油,备用;
(2)将槐花和西红花粉碎后先用10倍药材量的水进行浸泡5小时,再蒸馏提取6小时,收集挥发油,备用;
(3)将蒸馏后的水溶液滤过,药渣用7倍药材量的水煎煮1次,每次0.8h,滤过,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用药材质量的13倍的80%的乙醇作为提取液,在微波输出功率为650W下辐照13分钟进行提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理28分钟,静置18小时,滤过,滤液回收乙醇并减压浓缩至80℃时相对密度为1.12-1.20的浸膏;
(6)向浸膏中加入适量微粉硅胶,搅拌均匀,真空干燥后粉碎,过筛,加入95%的乙醇制粒,制粒后干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
对比例
该对比例同实施例1,与实施例1所不同的是步骤(1)和步骤(2)合并为采用如下方法:
将槐花、荷叶和西红花粉碎后先用10倍药材量的水进行浸泡6小时,再蒸馏提取7小时,收集挥发油,备用。
后续操作同实施例1。
试验例1
本试验例为药效试验。
1.实验动物
健康的SPF级S小鼠(雄性)50只。
2.实验分组及实验
将SD小鼠适应性喂养1周后,根据体重随机分成5组,每组10只。分别设为空白组、模型组(给予等量蒸馏水)、阳性对照组(给予别嘌醇)、给药组(实施例1和对比例制备得到的组合物)。除空白组、模型组给予等量蒸馏水,其余各组灌胃给予相应的药物,每天1次,连续给药7d后。除空白组外,其余各组连续给予氧嗪酸钾(250mg/kg)和灌胃含25%酵母膏饲料3周造模,在给予氧嗪酸钾和酵母膏前4h,给予药物治疗。造模型3周后,各组小鼠眼球取血,取血清测定血尿酸值。结果如表1所示。
表1
组别 | 只数 | 剂量(mg/kg·d) | 血尿酸值(μmol/L) |
空白组 | 10 | — | 261.3±0.45 |
模型组 | 10 | — | 451.2±0.37 |
实施例1 | 10 | 400 | 271.6±0.24 |
对比例 | 10 | 400 | 397.7±0.19 |
阳性组 | 10 | 50 | 278.9±0.41 |
与模型组相比,本发明实施例1制备得到的降尿酸组合物显示出较好的降尿酸作用,其效果接近阳性别嘌醇,表明本发明实施例1制备得到的降尿酸组合物具有较好的降尿酸作用。与对比例相比较,本发明的实施例1制备得到的降尿酸组合物的降尿酸效果显著,表明本发明的实施例1的制备方法能有效地提升组合物中功能成分的含量。
对本发明其他实施例所制得的降尿酸组合物也进行了上述试验,其获得的结果相似。
Claims (10)
1.一种降尿酸组合物,其特征在于,所述的降尿酸组合物由如下重量份的原料制成:
2.根据权利要求1所述的降尿酸组合物,其特征在于,所述的降尿酸组合物由如下重量份的原料制成:
3.一种权利要求1或2所述的降尿酸组合物的制备方法,其特征在于,所述的制备方法包括如下步骤:
(1)将荷叶粉碎、超临界CO2法提取挥发油,挥发油备用;
(2)将槐花和西红花粉碎后蒸馏法提取挥发油,挥发油备用;
(3)蒸馏后的水溶液滤过,得滤液,滤渣用水煎煮,滤过,得水煎液,合并滤液及水煎液成水提取物,药渣备用;
(4)将化橘红和车前草粉碎后,加入步骤(3)水煎后的药渣,用乙醇作为提取液,微波辐照提取;滤过,滤液备用;
(5)合并步骤(4)中滤液及步骤(3)中的水提取物,向合并液中加入乙醇至含醇量为70%,充分搅拌,超声处理,静置,滤过,滤液回收乙醇并减压浓缩成浸膏;
(6)向浸膏中加入药学上可接受的辅料,搅拌均匀,真空干燥后粉碎,过筛,制粒,干燥,得到干颗粒;
(7)将步骤(1)和步骤(2)备用的挥发油均匀喷入干颗粒,灌装,制成降尿酸中药组合物。
4.根据权利要求3所述的制备方法,其特征在于,步骤(1)中,所述的超临界CO2法为:将荷叶粉碎后所得的干粉置于超临界CO2萃取釜中,在温度为45-50℃、压力为25-30MPa、CO2流量为20-25kg/h的条件下萃取1.5-2h,收集挥发油。
5.根据权利要求3所述的制备方法,其特征在于,步骤(4)中,所述的微波辐照提取为:在微波输出功率为500W-800W下辐照10-18分钟进行提取。
6.根据权利要求5所述的制备方法,其特征在于,步骤(4)中,所述的乙醇为65-85%的乙醇,其用量为药材质量的10-15倍。
7.根据权利要求3所述的制备方法,其特征在于,步骤(5)中,超声处理时间为20-30分钟,静置时间为10-20小时。
8.根据权利要求3所述的制备方法,其特征在于,步骤(5)中,所述的减压浓缩为减压浓缩至80℃时相对密度为1.12-1.20的浸膏。
9.根据权利要求3所述的制备方法,其特征在于,所述的步骤(3)为:将蒸馏后的水溶液滤过,药渣用5-10倍药材量的水煎煮1-3次,每次0.5-1.5h,滤过,合并滤液及水煎液成水提取物,药渣备用。
10.根据权利要求3所述的制备方法,其特征在于,所述的药学上可接受的辅料为淀粉、糊精、乳糖、羟甲基纤维素钠或微粉硅胶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310502801.7A CN116459304A (zh) | 2023-05-06 | 2023-05-06 | 一种降尿酸组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310502801.7A CN116459304A (zh) | 2023-05-06 | 2023-05-06 | 一种降尿酸组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116459304A true CN116459304A (zh) | 2023-07-21 |
Family
ID=87184296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310502801.7A Pending CN116459304A (zh) | 2023-05-06 | 2023-05-06 | 一种降尿酸组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116459304A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118021750A (zh) * | 2024-04-11 | 2024-05-14 | 赣江新区清芝康医药科技有限公司 | 一种清咽利喉胶囊的制备方法 |
-
2023
- 2023-05-06 CN CN202310502801.7A patent/CN116459304A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118021750A (zh) * | 2024-04-11 | 2024-05-14 | 赣江新区清芝康医药科技有限公司 | 一种清咽利喉胶囊的制备方法 |
CN118021750B (zh) * | 2024-04-11 | 2024-06-11 | 赣江新区清芝康医药科技有限公司 | 一种清咽利喉胶囊的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116459304A (zh) | 一种降尿酸组合物及其制备方法 | |
CN109700939B (zh) | 铁皮石斛叶、黄精和莱菔子在制备治疗高血压药物中应用 | |
CN107751993A (zh) | 一种抗疲劳膏滋及其制备方法 | |
CN102813747B (zh) | 一种治疗***性红斑狼疮的中药 | |
CN108210547A (zh) | 一种余甘子叶提取物的制备方法及其制剂与抗艾应用 | |
CN112843140B (zh) | 一种治疗糖尿病导致口渴目赤的药物及制备方法和用途 | |
CN113521140B (zh) | 治疗高血粘导致心脑缺血引发头晕头痛、胸闷气短的药物 | |
CN102106896B (zh) | 中药材土千年健在制药中的新应用 | |
CN112022939A (zh) | 一种用于高血压合并高脂血症的胶囊及其制备方法 | |
CN112826917A (zh) | 一种复方桑葚黄芪中药组合物及其应用 | |
CN102335276B (zh) | 一种牡丹提取物及其组合物的制备方法及其应用 | |
CN101040905B (zh) | 用夏枯草制备的降血糖药物 | |
CN107684574B (zh) | 具有降血脂功能的药食两用组合物及其制备方法 | |
CN111529575A (zh) | 一种治疗痛风和/或高尿血酸症的药物组合物及制备方法 | |
CN110651858A (zh) | 一种降尿酸、缓解痛风的袋泡茶及其制备方法 | |
CN111150811A (zh) | 一种降血糖散粉的配方 | |
CN105343206B (zh) | 一种降血压、血脂的复配中药提取物及其制备方法 | |
CN109157556A (zh) | 蒲公英抗呼吸道感染成分的提取方法及应用 | |
CN115531471B (zh) | 一种抗非洲猪瘟的组合物及其制备方法和应用 | |
CN104740345B (zh) | 治疗糖尿病的中药组合物及其制备方法 | |
CN102631486B (zh) | 一种保健组合物 | |
CN103099886A (zh) | 有助于改善肠胃功能的软胶囊及其制备方法 | |
CN114507297B (zh) | 一种桦树茸多糖提取物的制备及应用 | |
AU2020101397A4 (en) | A pharmaceutical composition for the treatment of prostatic hyperplasia | |
CN109718320B (zh) | 一种降尿酸的功能饮料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |